Josep Garcia

2.6k total citations · 1 hit paper
33 papers, 1.4k citations indexed

About

Josep Garcia is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Josep Garcia has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Josep Garcia's work include Glioma Diagnosis and Treatment (23 papers), Radiomics and Machine Learning in Medical Imaging (9 papers) and Brain Metastases and Treatment (8 papers). Josep Garcia is often cited by papers focused on Glioma Diagnosis and Treatment (23 papers), Radiomics and Machine Learning in Medical Imaging (9 papers) and Brain Metastases and Treatment (8 papers). Josep Garcia collaborates with scholars based in Switzerland, France and United Kingdom. Josep Garcia's co-authors include Olivier Chinot, Herbert I. Hurwitz, Robert L. Coleman, Alan B. Sandler, David Miles, Regula Deurloo, Frank Saran, Wolfgang Wick, Timothy F. Cloughesy and Ryo Nishikawa and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Clinical Cancer Research.

In The Last Decade

Josep Garcia

31 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

2020 780 citations Josep Garcia, Herbert I. Hurwitz et al. Cancer Treatment Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Josep Garcia Switzerland	12	473	471	442	374	354	33	1.4k
Vincenzo Di Nunno Italy	21	448 0.9×	353 0.7×	524 1.2×	409 1.1×	594 1.7×	103	1.4k
Mikael Johansson Sweden	20	826 1.7×	422 0.9×	483 1.1×	619 1.7×	449 1.3×	44	1.8k
Maria Martinez‐García Spain	18	386 0.8×	287 0.6×	675 1.5×	318 0.9×	389 1.1×	81	1.3k
Zhenhua Zhai China	14	685 1.4×	201 0.4×	484 1.1×	356 1.0×	251 0.7×	22	1.4k
Estela Pineda Spain	16	624 1.3×	271 0.6×	669 1.5×	692 1.9×	354 1.0×	65	1.6k
Dana T. Aftab United States	20	803 1.7×	179 0.4×	882 2.0×	417 1.1×	574 1.6×	45	1.8k
Takafumi Sangai Japan	26	877 1.9×	267 0.6×	979 2.2×	444 1.2×	317 0.9×	78	2.1k
Garry Schwartz United States	24	760 1.6×	336 0.7×	1.1k 2.4×	323 0.9×	725 2.0×	40	2.0k
Naren Ramakrishna United States	24	639 1.4×	514 1.1×	968 2.2×	315 0.8×	920 2.6×	56	2.2k
Mythili Shastry United States	15	396 0.8×	120 0.3×	706 1.6×	291 0.8×	235 0.7×	38	1.2k

Countries citing papers authored by Josep Garcia

Since Specialization

Citations

This map shows the geographic impact of Josep Garcia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josep Garcia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josep Garcia more than expected).

Fields of papers citing papers by Josep Garcia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josep Garcia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josep Garcia. The network helps show where Josep Garcia may publish in the future.

Co-authorship network of co-authors of Josep Garcia

This figure shows the co-authorship network connecting the top 25 collaborators of Josep Garcia. A scholar is included among the top collaborators of Josep Garcia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josep Garcia. Josep Garcia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berz, David, Olatunji B. Alese, David S. Hong, et al.. (2025). Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study.. Journal of Clinical Oncology. 43(4_suppl). 129–129. 1 indexed citations

Matsubara, Nobuaki, Johann S. de Bono, Christopher Sweeney, et al.. (2023). Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(2). 230–237.e1. 5 indexed citations

Ellingson, Benjamin M., Akifumi Hagiwara, Nicholas S. Cho, et al.. (2023). Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. Clinical Cancer Research. 29(20). 4186–4195. 5 indexed citations

Kotani, Naoki, Justin Wilkins, Janet R. Wade, et al.. (2022). Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. Cancer Chemotherapy and Pharmacology. 90(6). 511–521. 4 indexed citations

Hagiwara, Akifumi, Catalina Raymond, Hiroyuki Tatekawa, et al.. (2022). Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation. Journal of Neuro-Oncology. 159(3). 509–518. 11 indexed citations

Johnson, Radia Marie, Heidi Phillips, Carlos Bais, et al.. (2020). Development of a gene expression–based prognostic signature for IDH wild-type glioblastoma. Neuro-Oncology. 22(12). 1742–1756. 19 indexed citations

Bono, Johann S. de, Sergio Bracarda, Cora N. Sternberg, et al.. (2020). LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S1153–S1154. 22 indexed citations

Garcia, Josep, Herbert I. Hurwitz, Alan B. Sandler, et al.. (2020). Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews. 86. 102017–102017. 780 indexed citations breakdown →

Gutierrez, Daniel Rodriguez, Monika Warmuth‐Metz, Esther Sánchez Aliaga, et al.. (2019). Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. American Journal of Neuroradiology. 40(3). 568–575. 3 indexed citations

10.

Mackay, Alan, Anna Burford, Valeria Molinari, et al.. (2017). HGG-03. INTEGRATED MOLECULAR AND PATHOLOGICAL CHARACTERISATION OF NON-BRAINSTEM PAEDIATRIC HIGH GRADE GLIOMA FROM THE HERBY PHASE II RANDOMISED TRIAL. Neuro-Oncology. 19(suppl_4). iv23–iv23. 1 indexed citations

11.

Nowosielski, Martha, Benjamin M. Ellingson, Olivier Chinot, et al.. (2017). Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio. Neuro-Oncology. 20(4). 557–566. 23 indexed citations

12.

Jaspan, Tim, Paul S. Morgan, Monika Warmuth‐Metz, et al.. (2016). Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. American Journal of Neuroradiology. 37(9). 1581–1587. 23 indexed citations

13.

Chinot, Olivier, Ryo Nishikawa, Warren Mason, et al.. (2016). Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-Oncology. 18(9). 1313–1318. 32 indexed citations

14.

Ellingson, Benjamin M., Josep Garcia, Cédric Révil, et al.. (2016). Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo.. Journal of Clinical Oncology. 34(15_suppl). 2021–2021. 2 indexed citations

15.

Chinot, Olivier, Josep Garcia, Sylvie Romain, et al.. (2016). ACTR-19. BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio. Neuro-Oncology. 18(suppl_6). vi5–vi5.

16.

Grill, Jacques, Darren Hargrave, Maura Massimino, et al.. (2016). HG-128BO25041 - A PHASE II OPEN-LABEL, RANDOMIZED, MULTI CENTRE COMPARATIVE STUDY OF BEVACIZUMAB BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR HIGH GRADE GLIOMA. Neuro-Oncology. 18(suppl 3). iii77.4–iii77. 1 indexed citations

17.

Sandmann, Thomas, Richard Bourgon, Josep Garcia, et al.. (2015). Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology. 33(25). 2735–2744. 208 indexed citations

18.

Mason, Warren, Timothy F. Cloughesy, Wolfgang Wick, et al.. (2014). Overview of Arterial Thromboembolic Events (ATEs) in AVAglio, a Randomized, Placebo-controlled Phase III Trial of Bevacizumab, Radiotherapy and Temozolomide (BEV+RT/TMZ) for Newly Diagnosed Glioblastoma (S22.003). Neurology. 82(10_supplement). 1 indexed citations

19.

Wick, Wolfgang, Timothy F. Cloughesy, Warren Mason, et al.. (2013). Efficacy and biomarker findings from AVaglio, a phase III trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma. Journal of the Neurological Sciences. 333. e654–e654. 3 indexed citations

20.

Cooney, Matthew M., Josep Garcia, Joanna M. Brell, et al.. (2007). A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 15532–15532. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact